

# Abhilash Venugopalan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9338424/publications.pdf>

Version: 2024-02-01

14  
papers

442  
citations

933447

10  
h-index

1199594

12  
g-index

15  
all docs

15  
docs citations

15  
times ranked

1126  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1195-1206.  | 4.1 | 18        |
| 2  | SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma. <i>Oncogene</i> , 2021, 40, 3331-3346.   | 5.9 | 6         |
| 3  | Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 4977.  | 3.7 | 5         |
| 4  | Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. <i>Cell Reports Medicine</i> , 2020, 1, 100007.   | 6.5 | 78        |
| 5  | APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. <i>Cell Reports</i> , 2019, 26, 2651-2666.e6.   | 6.4 | 92        |
| 6  | Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 622-641.   | 3.8 | 15        |
| 7  | Abstract 4528: Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V. , 2019, , .  |     | 0         |
| 8  | Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 891-910.   | 3.8 | 42        |
| 9  | Abstract 2927: Proteogenomic heterogeneity in metastatic lung adenocarcinoma revealed from rapid/warm autopsy. , 2017, , .   |     | 0         |
| 10 | Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001263. | 1.2 | 18        |
| 11 | EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. <i>Oncotarget</i> , 2016, 7, 54137-54156.  | 1.8 | 27        |
| 12 | Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2015, 5, 534-549.   | 9.4 | 57        |
| 13 | Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. <i>Proteomics</i> , 2015, 15, 340-355.  | 2.2 | 42        |
| 14 | A proteogenomic approach to map the proteome of an unsequenced pathogen "Leishmania donovani". <i>Proteomics</i> , 2012, 12, 832-844.  | 2.2 | 42        |